US 11,786,525 B1
High-efficiency anti-tumor nano-drug delivery system containing hydralazine and preparation method thereof
Ruhong Zhou, Stormville, NY (US); and Lianxue Zhang, Hangzhou (CN)
Assigned to SHANGHAI INSTITUTE FOR ADVANCED STUDY ZHE JIANG UNIVERSITY, Shanghai (CN)
Filed by SHANGHAI INSTITUTE FOR ADVANCED STUDY ZHE JIANG UNIVERSITY, Shanghai (CN)
Filed on Mar. 2, 2023, as Appl. No. 18/116,817.
Claims priority of application No. 2022110513925 (CN), filed on Aug. 31, 2022.
Int. Cl. A61K 31/502 (2006.01); A61K 31/704 (2006.01); A61K 9/51 (2006.01); A61P 35/00 (2006.01); B82Y 5/00 (2011.01); B82Y 40/00 (2011.01)
CPC A61K 31/502 (2013.01) [A61K 9/5161 (2013.01); A61K 9/5192 (2013.01); A61K 31/704 (2013.01); A61P 35/00 (2018.01); B82Y 5/00 (2013.01); B82Y 40/00 (2013.01)] 5 Claims
OG exemplary drawing
 
1. An anti-tumor nano-drug delivery system containing hydralazine (HDZ), wherein the anti-tumor nano-drug delivery system is hydralazine-nanoparticles (H-NPs) with a hydrophobic core of both doxorubicin and the hydralazine and is assembled by Dex-hyd-DOX/cRGD and the hydralazine together; and the Dex-hyd-DOX/cRGD is a cRGD polypeptide dextran-doxorubicin prodrug with pH responsiveness and tumor targeting.